Literature DB >> 34331819

Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.

R Ottevanger1, S van Beugen2, A W M Evers2, R Willemze1, M H Vermeer1, K D Quint1.   

Abstract

Cutaneous T-cell Lymphoma's (CTCL) are a rare, heterogeneous group of T-cell lymphomas that primarily manifest in the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) are considered the classic types of CTCL. The diverse manifestation of CTCL results in a wide range of symptoms with a possible mild to severe impact on Quality of Life (QoL) depending on the disease stage. Previous studies on QoL in CTCL patients report diverse patient populations and use many different QoL instruments. In the current literature, a clear overview on the influence of the different stages of disease (early MF, late-stage MF/SS or total group) on the QoL is lacking. Therefore, a systematic search of the literature was conducted using the PubMed, Embase, PsycINFO and Web of Science databases. Studies were included if they described QoL in patients with MF and SS retrieved by standardized instruments or qualitative interviews. In total, 24 studies were included using 18 different questionnaires to report on dermatology-specific, cancer-specific and generic QoL. The effect on QoL was found to be greater in patients with late-stage disease as compared to early stage disease, with significant impairments on functional, emotional and physical domains. Nonetheless, even in patients with limited disease, QoL was mildly to moderately affected. Overall, pruritus was the most frequent reported and most bothersome symptom. Significant influence of the disease on daily life activities were found, not only in patients but also on caregivers and family. This broad, structured overview on QoL in MF and SS patients underlines the influence of disease stage on QoL, and therefore, recommends future studies to distinguish between disease stages when reporting results. Furthermore, this overview can inform clinicians in clinical practice by creating awareness of QoL deficits according to disease stage.
© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2021        PMID: 34331819      PMCID: PMC9291074          DOI: 10.1111/jdv.17570

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   9.228


  51 in total

1.  Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.

Authors:  N Booken; M Heck; J P Nicolay; C D Klemke; S Goerdt; J Utikal
Journal:  Br J Dermatol       Date:  2011-01-28       Impact factor: 9.302

2.  Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis.

Authors:  Marie-France Demierre; Pascal Ferzli; Donald Miller
Journal:  Arch Dermatol       Date:  2007-05

3.  An inventory for measuring clinical anxiety: psychometric properties.

Authors:  A T Beck; N Epstein; G Brown; R A Steer
Journal:  J Consult Clin Psychol       Date:  1988-12

4.  'We had to change to single beds because I itch in the night': a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma.

Authors:  T Beynon; L Selman; E Radcliffe; S Whittaker; F Child; D Orlowska; C Morgans; S Morris; R Harding
Journal:  Br J Dermatol       Date:  2015-05-28       Impact factor: 9.302

5.  The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review.

Authors:  Mehul Dalal; Stephen Mitchell; Conor McCloskey; Erin Zagadailov; Ashish Gautam
Journal:  Expert Rev Hematol       Date:  2020-01-31       Impact factor: 2.929

6.  Patients' Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas.

Authors:  Stefanie Porkert; Eva Lehner-Baumgartner; Julia Valencak; Robert Knobler; Elisabeth Riedl; Constanze Jonak
Journal:  Acta Derm Venereol       Date:  2018-02-07       Impact factor: 4.437

7.  Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument.

Authors:  W L Ward; E A Hahn; F Mo; L Hernandez; D S Tulsky; D Cella
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

8.  Quality of life and psychological distress in patients with cutaneous lymphoma.

Authors:  F Sampogna; M Frontani; G Baliva; G A Lombardo; G Alvetreti; C Di Pietro; S Tabolli; G Russo; D Abeni
Journal:  Br J Dermatol       Date:  2008-12-16       Impact factor: 9.302

9.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.

Authors:  Matthew J Page; Joanne E McKenzie; Patrick M Bossuyt; Isabelle Boutron; Tammy C Hoffmann; Cynthia D Mulrow; Larissa Shamseer; Jennifer M Tetzlaff; Elie A Akl; Sue E Brennan; Roger Chou; Julie Glanville; Jeremy M Grimshaw; Asbjørn Hróbjartsson; Manoj M Lalu; Tianjing Li; Elizabeth W Loder; Evan Mayo-Wilson; Steve McDonald; Luke A McGuinness; Lesley A Stewart; James Thomas; Andrea C Tricco; Vivian A Welch; Penny Whiting; David Moher
Journal:  BMJ       Date:  2021-03-29

10.  The Health Utilities Index (HUI): concepts, measurement properties and applications.

Authors:  John Horsman; William Furlong; David Feeny; George Torrance
Journal:  Health Qual Life Outcomes       Date:  2003-10-16       Impact factor: 3.186

View more
  6 in total

Review 1.  [New treatment concepts and combination therapies for cutaneous T-cell lymphomas].

Authors:  Chalid Assaf; Gabor Dobos
Journal:  Dermatologie (Heidelb)       Date:  2022-09-08

Review 2.  [Quality of life of patients with mycosis fungoides and Sézary syndrome].

Authors:  Manuel Jäger; Deniz Özistanbullu; Claus-Detlev Klemke; Sabine Tratzmiller
Journal:  Dermatologie (Heidelb)       Date:  2022-09-08

Review 3.  Quality of Life and Survivorship in Lymphoma.

Authors:  Allison Rosenthal
Journal:  Curr Oncol Rep       Date:  2022-04-08       Impact factor: 5.945

4.  Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: Results of a pilot study.

Authors:  Dorothea Terhorst-Molawi; Katharina Lohse; Katharina Ginter; Viktoria Puhl; Martin Metz; Man Hu; Marcus Maurer; Sabine Altrichter
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

5.  Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator.

Authors:  Rosanne Ottevanger; Sylvia van Beugen; Andrea W M Evers; Rein Willemze; Maarten H Vermeer; Koen D Quint
Journal:  JAAD Int       Date:  2022-08-07

Review 6.  The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.

Authors:  Denis Miyashiro; Bruno de Castro E Souza; Marina Passos Torrealba; Kelly Cristina Gomes Manfrere; Maria Notomi Sato; José Antonio Sanches
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.